Meta-analysis of Efficacy of Topotecan

This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cervical Intraepithelial Neoplasia Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Neoplasms Precancerous Conditions Urogenital Diseases Uterine Cervical Diseases Uterine Cervical Dysplasia Uterine Diseases

Age range

21 year and older

Sex eligibility

Female

Study type

Observational

About this study

Studies included in the meta-analysis were: GOG-0179, GOG-0204 & GOG-0169

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Randomised Clinical Trials or systematic reviews or meta-analyses
Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease

Exclusion criteria

None

Treatment and study plan

paclitaxel

Drug

paclitacel

Cisplatin

Drug

cisplatin monotherapy

Topotecan

Drug

topotecan

Primary outcomes

Survival

Time frame: 12 months

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix

Important dates

Study start: 2009
Primary completion: 2009
Study completion: 2009
First posted: Jul 12, 2010
Registry last updated: Jul 12, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed